$EW

CMS expanded Medicare coverage for Edwards Lifesciences' TAVR procedure to asymptomatic severe aortic stenosis patients. The company reiterated its 10-11% sales growth guidance. Shares (EW) fell 2.7% to $84.37. Analysts see upside, with Jefferies raising its price target to $105.

BD appointed Gary Sorsher, former Chief Quality Officer at Edwards Lifesciences, as its new Executive Vice President and Chief Quality Officer. Sorsher brings over 30 years of experience in quality roles. The move follows Jeffrey Silvestri's planned retirement. BD's CEO highlighted Sorsher's global experience and focus on continuous improvement. Edwards Lifesciences received FDA clearance for its Ecliptis left atrial appendage exclusion system, entering the surgical stroke-prevention market. BD

Edwards Lifesciences (EW) and Medtronic (MDT) welcomed CMS's decision to expand Medicare coverage for TAVR to asymptomatic severe aortic stenosis patients, citing improved access and streamlined care. EW shares fell 2% to $84.31, MDT dropped 1% to $90.70. CMS's decision was based on EW's Early TAVR trial data, showing lower adverse outcomes for prompt TAVR. Analysts view the decision as positive for TAVR growth.

Canaccord maintained a Hold rating and $85 price target for Edwards Lifesciences (EW) after a Medicare coverage decision on TAVR procedures. The stock trades at $86.77, above the target but below consensus. CMS finalized changes Edwards requested, expanding coverage for asymptomatic severe aortic stenosis. Edwards confirmed its 2026 financial guidance, expecting long-term benefits. Analysts have mixed price targets, ranging from $84 to $110. The company reported strong Q2 results, with sales of

CMS finalized TAVR coverage, benefiting Edwards Lifesciences due to its market leadership. Stifel analysts view the update positively, supporting Edwards' revenue growth outlook. TAVR represents 75% of Edwards' revenues and 5.5% of Medtronic's. CMS also initiated coverage analysis for devices treating aortic regurgitation, including Edwards' J-Valve.

The Centers for Medicare & Medicaid Services expanded coverage for Edwards Lifesciences' TAVR technologies to asymptomatic aortic stenosis. Edwards Lifesciences stated this update improves patient access and reinforces the value of a multidisciplinary Heart Team. Shares of Edwards Lifesciences (NYSE: EW) closed at $86.77, with a market cap of $50 billion.

Edwards Lifesciences (EW) responded to the CMS's updated national coverage determination (NCD) for TAVR, expressing support for improved patient access and streamlined care. The company reaffirmed its 2026 financial guidance and will provide 2027 and long-term guidance in December. Edwards remains committed to working with stakeholders for the policy's implementation.

Edwards Lifesciences (EW), a large-cap medical device company, has seen its stock underperform the Dow Jones Industrial Average over the past three and twelve months. Despite this, EW has shown bullish momentum, trading above its 200-day and 50-day moving averages, and reported strong Q2 2026 earnings with 13.6% sales growth and raised its 2026 sales growth guidance. Analysts rate it a 'Strong Buy' with a mean price target of $102.03.

Edwards Lifesciences (EW) officer Andrew M. Dahl plans to sell up to 544 shares, worth $49,534, under Rule 144. The shares are tied to a restricted stock lapse scheduled for May 8, 2026, and are part of equity compensation. The company has 576.4 million shares outstanding.

Unusually high volume of out-of-the-money put options in Edwards Lifesciences (EW) suggests investor bullishness. EW is trading at $90.78, below analysts' price targets. The company reported strong Q2 earnings and raised 2026 EPS guidance. Analysts project 2027 EPS of $3.38, implying a forward P/E of 28.5x, below its 5-year average of 33.35x.